A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use Disorder
Completed · Phase 2 · NCT06817356
Conditions: Alcohol Use Disorder
At a glance
- Research payments reported, 2025
- $6,907
- U.S. investigators named
- 18
- Sites paid
- 11
- Planned or actual enrollment
- 308
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- Mazdutide (drug), Placebo (drug)
- Dates
- Started 2025-02-06; completion 2026-05-19
- Results posted
- Not yet
The objective of this proof-of-concept study to evaluate mazdutide in participants with alcohol use disorder (AUD). For any individual participant, the maximum duration of study participation is approximately 36 weeks, including screening and posttreatment follow-up.
From ClinicalTrials.gov, last updated 2026-07-16. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $6,907 in research payments for this study in 2025 (27 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Eric M. Chavez, MD Psychiatry · San Diego, CA
- Justin L. Yanuck, M.D. Emergency Medicine · Downey, CA
- Edwin A. Gomez, M.D. Psychiatry · Weston, FL
- John M. Joyce, M. D. Psychiatry · Jacksonville, FL
- Robert B. Molpus, MD Psychiatry · Longwood, FL
- Kelley A. Wilson, M.D. Psychiatry · Tampa, FL
- Kimball A. Johnson, MD Internal Medicine · Atlanta, GA
- Brady Bradshaw, MD Child & Adolescent Psychiatry · Hiawatha, IA
- Rachael M. Murphy, M.D. Internal Medicine · Covington, LA
- Daniel Rutrick, M.D. Specialist · Watertown, MA
- Shenif Ladak, M.D. Physical Medicine & Rehabilitation (PM&R) · Bridgeton, MO
- Beal Essink, MD Psychiatry · Salem, OR
- John A. Stoukides, MD Geriatric Medicine · East Providence, RI
- Sarah W. Book, MD Psychiatry · Charleston, SC
- Sejal Patel, M.D. Military Health Care Provider · Columbia, SC
- Lora J. Mcgill, M.D. Neurology · Memphis, TN
- Michael J. Downing, MD Psychiatry · Dallas, TX
- Brandon Lawrence, M.D. Orthopedic Surgery · Salt Lake City, UT
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- $2,663
- K2 Medical Research LLC $1,289
- Clinical Neuroscience Solutions DBA Cns Hlthcare $470
- Ark Clinical Research LLC $448
- Headlands Horizons LLC $448
- Cenexel Iresearch LLC $347
- Adams Clinical LLC $224
- Medex Healthcare Research Inc $224
- Artemis Headlands LLC $224
- Future Search Trials of Dallas LP $224
- University of South Carolina $224
- Delricht LLC $123
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.